UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

October 28, 2021

(Commission File No. 001-40505)

 

 

Ambrx Biopharma Inc.

(Translation of registrant’s name into English)

 

 

Cayman Islands

(Jurisdiction of incorporation or organization)

10975 Torrey Pines Road

La Jolla, California 92037

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

Earnings Release

On October 28, 2021, Ambrx Biopharma Inc. issued a press release regarding its financial results as of and for the six months ended June 30, 2021 and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1.

Exhibits

 

Exhibit
Number

  

Exhibit Description

99.1    Press release, dated October 28, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

Ambrx Biopharma Inc.

By:

 

/s/ Feng Tian

Name:

 

Feng Tian, Ph.D.

Title:

 

Chief Executive Officer

Date: October 28, 2021

Ambrx Biopharma (NYSE:AMAM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Ambrx Biopharma
Ambrx Biopharma (NYSE:AMAM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Ambrx Biopharma